The clinical effects and safty of cyclosporine with rootine corticosteroid treatment in onset MCNS

The clinical effects and safty of cyclosporine with rootine corticosteroid treatment in onset MCNS - The effects of cyclosporine in onset MCNS

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004653

Enrollment

Registered

2010-12-02

Start date

2005-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

minimal change nephrotic syndrome

Interventions

cyclosporine A 2-3mg/kg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: minimal change nephrotic syndrome patients that do not have underlying disease

Exclusion criteria

Exclusion criteria: minimal change nephrotic syndrome patients that have underlying disease

Design outcomes

Primary

Measure	Time frame
shortening of hospitalization, reduction in adverse effects, prevention of relapse, reduction in dose of corticosteroid	—

Secondary

Measure	Time frame
reduction in days required for complete remission, blood and urine chemistry data of 6 and 12 months after discharge	—

Countries

Japan

Contacts

Public ContactNobuhito hirawa

Yokohama city university medical center division of Nephrology and Hypertension

045-261-5656

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026